eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
4/2007
vol. 11
 
Share:
Send email
Share:
abstract:

Anthracycline-induced cardiomyopathy, an essential diagnostic and therapeutic problem in oncological practice

Elżbieta Bręborowicz
,
Piotr Bręborowicz
,
Maria Litwiniuk
,
Piotr Tomczak

Współczesna Onkologia (2007) vol. 11; 4 (204-209)
Online publish date: 2007/06/19
View full text Get citation
 
For many years, anthracyclines have been used in chemotherapy. Nowadays, cytostatic therapy prolongs survival of patients, but in some it produces a cardiotoxic effect, which leads to iatrogenic myocardial injury and cardiomyopathy with symptoms of heart failure. In chemotherapy departments, the oncologist has become responsible for cardiotoxicity risk stratification in patients undergoing/planned for anthracycline therapy and early recognition of cardiac complications. Monitoring of left ventricular function is now an essential part of oncological procedures using cardiotoxic drugs. ACE inhibitors, AT1 receptor blockers, betablockers, diuretics and digoxin are drugs of choice in heart failure therapy
keywords:

anthracycline-induced cardiomyopathy, cardiotoxicity, anthracyclines
FEATURED PRODUCTS
BOOKS
• Genetyka i leczenie chłoniaka rozlanego z dużych komórek B (DLBCL)
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.